← Stock Trading Canary · All insider profiles
INSIDER PROFILE · UK
Robert Lyne Sharon Barber-Lui John LaMattina Michele Holcomb
Robert Lyne - Chief Executive Officer, Executive Director Sharon Barber-Lui - Interim Board Chair; Non-Executive Director John LaMattina - Non-Executive Director Michele Holcomb - Non-Executive Director | Robert Lyne - Interim Chief Executive Officer Sharon Barber-Lui - Interim Board Chair; Non-Executive Director John LaMattina - Non-Executive Director Michele Holcomb - Non-Executive Director
Profile key: uk|robert lyne sharon barber-lui john lamattina michele holcomb
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 4
- Purchases · 24M
- 8
- Average purchase
- £55,599
- Gross purchase value
- £333,592
- Last purchase
- 2026-07-08
- Completed 20D events
- 2.0
- Outcome status
- INSUFFICIENT_SAMPLE
Latest company: PureTech Health plc
Companies: PureTech Health plc
Post-purchase outcomes
Benchmark-relative outcomes are available against FTSE 100.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +6.0% | +6.0% | +4.6% |
| 20D | 2Small sample | 100.0% (2/2) | 50.0% (1/2) | -1.8% | -1.8% | -6.1% |
| 60D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -10.1% | -10.1% | -10.6% |
| 120D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -16.9% | -16.9% | -16.9% |
Research patterns
- First purchase in 12M
- 1/2
- Large purchase ≥ €100k
- 2/2
- Cluster buying · 15D
- 0/2
- Buying the dip · ≥20% below prior 52W high
- 1/2
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.